Recently, the Jiangsu Province announced the winners of 2024 "Future Unicorn Enterprises of Jiangsu Province" and Biomissile Pharmaceuticals Co., Ltd. was honored to be selected.

About Future Unicorn Enterprises of Jiangsu Province

“Future Unicorn Enterprises of Jiangsu Province” refers to a select group of startups within the province, each valued at over $100 million and not yet publicly traded. These companies are distinguished by their robust innovation and their alignment with the vanguard of industry trends. Possessing pioneering technology and expansive market prospects, they are poised to lead in their respective industries. As vital catalysts for economic prosperity in Jiangsu Province and across the nation, they are at the forefront of driving industrial advancement and technological innovation.

About Biomissile

Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-M^TM molecules to specifically activate immune cells in the tumor microenvironment (TME). So far, two leading projects are in clinical stages (in Phase I & II) and the third one is in IND filing stage. 

Biomissile has successfully assembled a global, seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Shanghai, a future GMP facility in Suzhou, and a global regulatory & BD team in Boston, USA. We are committed to the disruptive innovation of biological drugs to benefit patients worldwide.

Link to the news in Chinese:
https://mp.weixin.qq.com/s?__biz=Mzg5MTc3NjcyMA==&mid=2247483873&idx=1&sn=085a00585e7f2b767ef2b271464b59eb&chksm=cfc97a5ef8bef348f4e8184f12c88564cbfead94e937bd79ce791640a94e3625bf7784601734&token=1275011442&lang=zh_CN#rd

BD: bd@biomissile.com
HR: hr@biomissile.com
Website: www.biomissile.com